Dr. Castillo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-6285- Is this information wrong?
Summary
- Dr. Jorge Castillo is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Dana-Farber Cancer Institute and Brigham and Women's Hospital. He received his medical degree from Autonomous Metropolitan University Xochimilco and has been in practice 21 years. He specializes in hematologic oncology and is experienced in Waldenstrom macroglobulinemia, lymphoma and myeloma.
Education & Training
Brown UniversityFellowship, Hematology and Medical Oncology, 2005 - 2008
MetroWest Medical CenterResidency, Internal Medicine, 2002 - 2005
Autonomous Metropolitan University XochimilcoClass of 1996
Certifications & Licensure
FL State Medical License 2022 - Present
MA State Medical License 2013 - 2026
NH State Medical License 2023 - 2025
RI State Medical License 2005 - 2014- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Honorary Professor Universidad San Martin de Porres, 2017
- Certificate of Excellence in Reviewing; Leukemia Research 2013
- Best Lymphoma Abstract 2012
- Join now to see all
Clinical Trials
- Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia Start of enrollment: 2015 Apr 01
- Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia Start of enrollment: 2015 Oct 01
- Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing Start of enrollment: 2016 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.Constantine S Tam, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee, Gavin Cull, Roger G Owen, Paula Marlton, Björn E Wahlin, Ramón García-Sanz, Helen McCart...> ;Blood Advances. 2024 Apr 9
- 1 citationsIbrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia.Jorge J Castillo, Andrew R Branagan, David Sermer, Catherine A Flynn, Kirsten Meid, Megan Little, Katherine Stockman, Timothy White, Alexa Canning, Maria L Guerrera, A...> ;Blood. 2024 Feb 15
- 1 citationsWaldenström Macroglobulinemia: Targeted Agents Taking Center Stage.Sarosiek, S., Castillo, J.> ;Drugs. 2024 Jan 1
- Join now to see all
Journal Articles
- TP53 Mutations Are Associated with Mutated MYD88 and CXCR4, and Confer an Adverse Outcome in Waldenström MacroglobulinaemiaToni Dubeau, Steven P Treon, Jorge J Castillo, Christopher J Patterson, British Journal of Haematology
- Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (Alliance) clinical trialsCastillo JJ, Mulkey F, Geyer S, Kolitz JE, Blum W, Powell BL, George SL,Larson RA, Stone RM, American Journal of Hematology, 1/3/2015
- Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom MacroglobulinemiaGhobrial IM, Redd R, Armand P, Boswell E, Chuma S, Huynh D, Sacco A, Roccaro A, Noonan K, Leblebjian H, Warren D, Henrick P, Castillo JJ, Richardson PG, Matous J, Well..., Leukemia, 1/3/2015
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Assessment of Different Biological Variables (Serum Albumin, _-2-Microglobulin, Lymphocyte/Monocyte ratio, Neutrophil/Lymphocyte ratio, Platelet/Lymphocyte ratio) in a...Jorge J. Castillo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Serum Albumin Is an Independent Factor Predicting Survival in Patients with Peripheral T Cell Lymphoma: A Multi-Institutional Study from the Latin American Working Gro...Jorge J. Castillo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Identifying a Simple Clinical Prognostic Model for Aggressive Adult T-Cell Leukemia/Lymphoma in Latin American Population and Its Validation: A Large International Stu...Jorge J Castillo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenstr_m Macroglobulinemia Treated with Ibrutinib61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- CXCR4 Mutational Status Does Not Impact Outcomes in Patients with Waldenstrom Macroglobulinemia Treated with Proteasome Inhibitors61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Genomic Analysis of Ibrutinib Resistance in Waldenstrom Macroglobulinemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Other
- Waldenstrom MacroglobulinemiaCastillo JJ, Ghobrial IM, Decision Support in Medicine (TM), Clinical Decision Support: Hematology
https://www.decisionsupportinmedicine.com
1/1/2014 - Autoimmune Hemolytic Anemia (including Evans Syndrome)Castillo JJ, Decision Support in Medicine (TM), Clinical Decision Support: Hematology
https://www.decisionsupportinmedicine.com
1/1/2013
Press Mentions
Researchers Devise a Progression Risk-Based Classification for Patients with Asymptomatic Waldenström MacroglobulinemiaApril 23rd, 2019- Study Shows Who Survives Burkitt LymphomaFebruary 10th, 2016
Professional Memberships
- Member
- Member
Hospital Affiliations
Dana-Farber Cancer InstituteBoston, Massachusetts
Brigham and Women's HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
